GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avacta Group PLC (LSE:AVCT) » Definitions » Research & Development

Avacta Group (LSE:AVCT) Research & Development : £14.53 Mil (TTM As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Avacta Group Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Avacta Group's Research & Development for the six months ended in Dec. 2023 was £8.52 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was £14.53 Mil.

Avacta Group Research & Development Historical Data

The historical data trend for Avacta Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avacta Group Research & Development Chart

Avacta Group Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.79 8.89 13.48 11.10 14.53

Avacta Group Semi-Annual Data
Jul13 Jan14 Jul14 Jan15 Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.22 6.00 5.10 6.01 8.52

Avacta Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £14.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avacta Group  (LSE:AVCT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Avacta Group Research & Development Related Terms

Thank you for viewing the detailed overview of Avacta Group's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Avacta Group (LSE:AVCT) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avacta Group PLC (LSE:AVCT) » Definitions » Research & Development
Comparable Companies
LSE:FARN LSE:4BB LSE:HVO LSE:FUM LSE:SCLP LSE:BVXP LSE:POLB LSE:AREC LSE:TRX LSE:SAR OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
AVCTF:USA RTQ1:Germany
Address
Unit 20, Ash Way, Thorp Arch Estate, West Yorkshire, Wetherby, GBR, LS23 7FA
Website
https://www.avacta.com
Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.

Avacta Group (LSE:AVCT) Headlines

No Headlines